Nectin-4在肌层浸润性膀胱癌中的空间分布及亚型特异性表达模式
研究在314例根治性膀胱切除患者的1386个组织芯中评估Nectin-4表达,发现63%原发肿瘤和87%淋巴结转移灶表达Nectin-4,淋巴结表达显著更高;微乳头和纯尿路上皮组织学阳性率最高,肉瘤样、鳞状和小/神经内分泌最低;Lund管腔亚型阳性率高于基底或间质亚型;高表达与较低肿瘤分期相关但与总生存无关;低表达患者倾向从铂类化疗获益更多(辅助P<0.001,新辅助P=0.067)。
要点
- Nectin-4在63%原发肿瘤和87%淋巴结转移灶中表达,淋巴结表达显著更高。
- 微乳头(58%)和纯尿路上皮(30%)组织学Nectin-4阳性率最高,小/神经内分泌为0%。
- Lund管腔亚型阳性率(尿路上皮样42%、基因组不稳定34%)高于基底(5%)或间质(0%)。
核心结论
- Nectin-4在原发肿瘤内空间异质性低,但在组织学和分子亚型间表达存在差异。
- 表达Nectin-4的肿瘤对EV和铂类化疗可能表现出不同敏感性。
研究设计与样本
- 研究纳入314例2005-2018年接受根治性膀胱切除的连续尿路上皮膀胱癌患者,构建含1386个组织芯的空间组织微阵列。
- 评估Nectin-4蛋白表达,并与临床病理、随访数据、空间位置(肿瘤中心 vs 肿瘤-正常交界、原发肿瘤 vs 淋巴结转移)及组织学和分子亚型进行关联分析。
- 评估Nectin-4表达对围手术期铂类治疗疗效的预测价值。
主要发现
- Nectin-4在63%原发肿瘤和87%淋巴结转移灶中表达,淋巴结表达水平显著更高。
- 组织学亚型中,微乳头(58%)和纯尿路上皮(30%)Nectin-4阳性率最高,肉瘤样(17%)、鳞状(15%)和小/神经内分泌(0%)最低。
- Lund管腔亚型阳性率(尿路上皮样42%、基因组不稳定34%)显著高于基底(5%)或间质(0%)分子亚型。
- 较高Nectin-4表达与较低肿瘤分期相关,但与总生存无关联。
- 低Nectin-4表达患者倾向从铂类化疗获益更多(辅助P<0.001,新辅助P=0.067)。
关键数值与推荐
- 原发肿瘤Nectin-4表达率63%,淋巴结转移灶87%。
- 微乳头组织学Nectin-4阳性率58%,纯尿路上皮30%,肉瘤样17%,鳞状15%,小/神经内分泌0%。
- Lund尿路上皮样亚型Nectin-4阳性率42%,基因组不稳定34%,基底5%,间质0%。
- 低Nectin-4表达与铂类化疗获益的关联:辅助治疗P<0.001,新辅助治疗P=0.067。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the expression patterns of Nectin-4, the target molecule of the antibody-drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder cancer (UBC). PATIENTS AND METHODS: We assessed the protein expression patterns of Nectin-4 in a spatially organised tissue microarray containing 1386 tissue cores from 314 consecutive patients with UBC who underwent radical cystectomy (2005-2018). Results were correlated with clinicopathological and follow-up data, as well as with different spatial locations (tumour central vs tumour-normal interface and primary tumour vs lymph node [LN] metastases). Additionally, we correlated Nectin-4 expression levels with histological and molecular subtypes. Finally, we assessed the value of Nectin-4 expression for predicting the efficacy of platinum therapy in the peri-operative setting. RESULTS: Nectin-4 expression was observed in 63% of primary tumours and 87% of LN metastases, with significantly higher levels in LNs. Of the histological subtypes, the micropapillary (58%) and pure urothelial histologies (30%) were associated with the highest Nectin-4 positivity, while the sarcomatoid (17%), squamous (15%) and small/cell-neuroendocrine (0%) subtypes exhibited the lowest. Nectin-4 immunopositivity rates were significantly higher in luminal (urothelial-like [42%] and genomically unstable [34%] Lund subtypes) compared to the basal (5%) or mesenchymal (0%) molecular subtypes. Higher Nectin-4 expression levels were associated with lower tumour stage but showed no association with overall survival. Finally, patients with low Nectin-4 expression tended to derive more benefit from platinum-based chemotherapy in both adjuvant and neoadjuvant settings (P < 0.001, P = 0.067). CONCLUSION: Our results revealed a low spatial heterogeneity of Nectin-4 expression within the primary tumour. In contrast, differential Nectin-4 expression was found in the context of histological and molecular subtypes. Nectin-4-expressing tumours may show varying sensitivity to both EV and platinum-based chemotherapy.
引用
- Olah C, Sichward L, Hadaschik B, et al. Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer. BJU Int. 2025. PMID: 39801278. doi:10.1111/bju.16643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。